Search Results - "Mark W. Konijnenberg"

Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome by Peters, Steffie M. B., Privé, Bastiaan M., de Bakker, Maarten, de Lange, Frank, Jentzen, Walter, Eek, Annemarie, Muselaers, Constantijn H. J., Mehra, Niven, Witjes, J. Alfred, Gotthardt, Martin, Nagarajah, James, Konijnenberg, Mark W.

“…Introduction While [ 177 Lu]Lu-PSMA radioligand therapy is currently only applied in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients,…”
Get full text

To go where no one has gone before: the necessity of radiobiology studies for exploration beyond the limits of the “Holy Gray” in radionuclide therapy by Verburg, Frederik A., Nonnekens, Julie, Konijnenberg, Mark W., de Jong, Marion

Get full text

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy by Ruigrok, Eline A. M., van Vliet, Nicole, Dalm, Simone U., de Blois, Erik, van Gent, Dik C., Haeck, Joost, de Ridder, Corrina, Stuurman, Debra, Konijnenberg, Mark W., van Weerden, Wytske M., de Jong, Marion, Nonnekens, Julie

“…Purpose Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting tracers are clinically applied for prostate cancer (PCa) imaging and targeted…”
Get full text

Urinary excretion kinetics of [177Lu]Lu-PSMA-617 by de Bakker, Maarten, Dominicus, Noa, Meeuwis, Antoi, Janssen, Marcel, Konijnenberg, Mark W., Nagarajah, James, Peters, Steffie M. B.

“…Introduction For the implementation of suitable radiation safety measures in [ 177 Lu]Lu-PSMA-617 therapy, additional insight into excretion kinetics is…”
Get full text

89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man by Privé, Bastiaan M., Derks, Yvonne H. W., Rosar, Florian, Franssen, Gerben M., Peters, Steffie M. B., Khreish, Fadi, Bartholomä, Mark, Maus, Stephan, Gotthardt, Martin, Laverman, Peter, Konijnenberg, Mark W., Ezziddin, Samer, Nagarajah, James, Heskamp, Sandra

“…Rationale Prolonged in vivo evaluation of PSMA tracers could improve tumor imaging and patient selection for 177 Lu-PSMA-617 and 177 Lu-PSMA-I&T. In this…”
Get full text

To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer by Roosen, Joey, Klaassen, Nienke J. M., Westlund Gotby, Lovisa E. L., Overduin, Christiaan G., Verheij, Marcel, Konijnenberg, Mark W., Nijsen, J. Frank W.

“…Purpose To systematically review all current evidence into the dose-response relation of yttrium-90 and holmium-166 selective internal radiation therapy (SIRT)…”
Get full text

[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment by Peters, Steffie M. B., Hofferber, Regina, Privé, Bastiaan M., de Bakker, Maarten, Gotthardt, Martin, Janssen, Marcel, de Lange, Frank, Muselaers, Constantijn H. J., Mehra, Niven, Witjes, J. Alfred, Costa, Pedro F., Nagarajah, James, Konijnenberg, Mark W., Jentzen, Walter

“…Introduction Patient eligibility for [ 177 Lu]Lu-PSMA therapy remains a challenge, with only 40–60% response rate when patient selection is done based on the…”
Get full text

Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma by Minczeles, Noémie S., Bos, Eelke M., de Leeuw, Reinoud C., Kros, Johan M., Konijnenberg, Mark W., Bromberg, Jacoline E. C., de Herder, Wouter W., Dirven, Clemens M. F., Hofland, Johannes, Brabander, Tessa

“…Purpose There is no evidence-based systemic therapy for patients with progressive meningiomas for whom surgery or external radiotherapy is no longer an option…”
Get full text

Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies by Verburg, Frederik A., Hoffmann, Martha, Iakovou, Ioannis, Konijnenberg, Mark W., Mihailovic, Jasna, Gabina, Pablo Minguez, Ovčariček, Petra Petranović, Reiners, Cristoph, Vrachimis, Alexis, Zerdoud, Slimane, Giovanella, Luca, Luster, Markus

Get full text

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection by Verburg, Frederik A., de Blois, Erik, Koolen, Stijn, Konijnenberg, Mark W.

“…Aim To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and…”
Get full text

[ 212 Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors by Chapeau, Dylan, Koustoulidou, Sofia, Handula, Maryana, Beekman, Savanne, de Ridder, Corrina, Stuurman, Debra, de Blois, Erik, Buchatskaya, Yulia, van der Schilden, Karlijn, de Jong, Marion, Konijnenberg, Mark W, Seimbille, Yann

“…Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is…”
Get full text

Towards standardization of absolute SPECT/CT quantification: a multi-center and multi-vendor phantom study by Peters, Steffie M. B., van der Werf, Niels R., Segbers, Marcel, van Velden, Floris H. P., Wierts, Roel, Blokland, Koos (J.) A. K., Konijnenberg, Mark W., Lazarenko, Sergiy V., Visser, Eric P., Gotthardt, Martin

“…Absolute quantification of radiotracer distribution using SPECT/CT imaging is of great importance for dosimetry aimed at personalized radionuclide precision…”
Get full text

Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems by Peters, Steffie M. B., Meyer Viol, Sebastiaan L., van der Werf, Niels R., de Jong, Nick, van Velden, Floris H. P., Meeuwis, Antoi, Konijnenberg, Mark W., Gotthardt, Martin, de Jong, Hugo W. A. M., Segbers, Marcel

“…Background Quantitative SPECT imaging in targeted radionuclide therapy with lutetium-177 holds great potential for individualized treatment based on dose…”
Get full text

Exploring the translational challenge for medical applications of ionising radiation and corresponding radiation protection research by Bockhold, Sophie, Foley, Shane J, Rainford, Louise A, Corridori, Riccardo, Eberstein, Annika, Hoeschen, Christoph, Konijnenberg, Mark W, Molyneux-Hodgson, Susan, Paulo, Graciano, Santos, Joana, McNulty, Jonathan P

“…Medical applications of ionising radiation and associated radiation protection research often encounter long delays and inconsistent implementation when…”
Get full text

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation by Peters, Steffie M. B., Mink, Maaike C. T., Privé, Bastiaan M., de Bakker, Maarten, de Lange, Frank, Muselaers, Constantijn H. J., Mehra, Niven, Witjes, J. Alfred, Gotthardt, Martin, Nagarajah, James, Konijnenberg, Mark W.

“…Background Dosimetry in [ 177 Lu]Lu-PSMA therapy is a valuable tool to assess treatment efficacy and toxicity. This study aims to develop a clinically…”
Get full text

Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity by Tamborino, Giulia, De Saint-Hubert, Marijke, Struelens, Lara, Seoane, Dayana C., Ruigrok, Eline A. M., Aerts, An, van Cappellen, Wiggert A., de Jong, Marion, Konijnenberg, Mark W., Nonnekens, Julie

“…Background Survival and linear-quadratic model fitting parameters implemented in treatment planning for targeted radionuclide therapy depend on accurate…”
Get full text

Treatment of [99mTc]Tc‐hydroxy‐diphosphonate ([99mTc]Tc‐HDP) extravasation using hyaluronidase by Doornhof, Kevin R., de Lussanet de la Sablonière, Quido, Koolen, Stijn L. W., Konijnenberg, Mark W.

“…Extravasation of 99mTc‐labeled radiopharmaceuticals is generally considered to require no specific intervention. In the presented case, the use of…”
Get full text

Accuracy of holmium-166 SPECT/CT quantification over a large range of activities by Westlund Gotby, Lovisa E. L., Lobeek, Daphne, Roosen, Joey, de Bakker, Maarten, Konijnenberg, Mark W., Nijsen, J. Frank W.

“…Background Quantitative imaging is a crucial step for dosimetry in radionuclide therapies. Traditionally, SPECT/CT imaging is quantified based on…”
Get full text

Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT by Grob, Dagmar, Privé, Bastiaan M., Muselaers, Constantijn H. J., Mehra, Niven, Nagarajah, James, Konijnenberg, Mark W., Peters, Steffie M. B.

“…Background Bone marrow toxicity in advanced prostate cancer patients who receive [ 177 Lu]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g…”
Get full text

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071 by Liu, Yongsheng, Vorobyeva, Anzhelika, Orlova, Anna, Konijnenberg, Mark W., Xu, Tianqi, Bragina, Olga, Loftenius, Annika, Rosander, Erica, Frejd, Fredrik Y., Tolmachev, Vladimir

“…HER2-targeted radionuclide therapy might be helpful for the treatment of breast, gastric, and ovarian cancers which have developed resistance to antibody and…”
Get full text